Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 10, Issue 9, 2015, Pages 1268-1278

  Baik, Christina S ^a   Chamberlain, Marc C ^a   Chow, Laura Q ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anaplastic lymphoma kinase; Brain metastases; Epidermal growth factor receptor; Non small cell lung cancer; Targeted therapy

Indexed keywords

AFATINIB; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BRIGATINIB; CERITINIB; CETUXIMAB; CRIZOTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; ROCILETINIB; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG PENETRATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; BRAIN TUMOR; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84940103252     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000615     Document Type: Review

References (103)

1. Herbst RS, Heymach JV, Lippman SM, Lung cancer. N Engl J Med 2008 359 1367 1380
2. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://seer.cancer.gov/data. Accessed September 24, 2014
3. Patchell RA, The management of brain metastases. Cancer Treat Rev 2003 29 533 540
4. NCCN Clinical Practice Guidelines: Non-Small Cell Lung Cancer, Version 3.2014. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#nscl. Accessed September 24, 2014
5. Mehta M, Vogelbaum MA, Chang S, DeVita VT Jr, Lawrence TS, Rosenberg SA, Neoplasms of the central nervous system. Cancer: Principles and Practice of Oncology 2011 9th Ed Philadelphia Lippincott Williams & Wilkins 1700 1749
6. Cruz-Muñoz W, Kerbel RS, Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol 2011 21 123 130
7. D'Antonio C, Passaro A, Gori B, Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 2014 6 101 114
8. Patchell RA, Tibbs PA, Walsh JW, A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990 322 494 500
9. Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 361 947 957
10. Shaw AT, Kim DW, Nakagawa K, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 368 2385 2394
11. Gori B, Ricciardi S, del Signore E, Fulvi A, de Marinis F, Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 2012 16 Suppl 2 S55 S60
12. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR, Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev 2013 39 839 850
13. Shaw AT, Engelman JA, ALK in lung cancer: past, present, and future. J Clin Oncol 2013 31 1105 1111
14. Iwama E, Okamoto I, Harada T, Takayama K, Nakanishi Y, Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 7 375 385
15. Deeken JF, Löscher W, The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007 13 1663 1674
16. Chamberlain M, Soffietti R, Raizer J, Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014 16 1176 1185
17. Kris MG, Johnson BE, Berry LD, Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014 311 1998 2006
18. Camidge DR, Bang YJ, Kwak EL, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 13 1011 1019
19. Costa DB, Kobayashi S, Pandya SS, CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011 29 e443 e445
20. Pardridge WM, The blood-brain barrier and neurotherapeutics. NeuroRx 2005 2 1 2
21. Löscher W, Potschka H, Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005 6 591 602
22. Löscher W, Potschka H, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005 76 22 76
23. Abbott NJ, Rönnbäck L, Hansson E, Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006 7 41 53
24. Kast RE, Focosi D, Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib. Transl Oncol 2010 3 13 15
25. Weber B, Winterdahl M, Memon A, Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011 6 1287 1289
26. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF, Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011 17 89 99
27. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O, Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012 30 443 449
28. Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH, Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014 134 1484 1494
29. Rosell R, Carcereny E, Gervais R, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 13 239 246
30. Sequist LV, Yang JC, Yamamoto N, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013 31 3327 3334
31. Weickhardt AJ, Scheier B, Burke JM, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012 7 1807 1814
32. Heon S, Yeap BY, Lindeman NI, The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012 18 4406 4414
33. Porta R, Sánchez-Torres JM, Paz-Ares L, Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011 37 624 631
34. Wu YL, Zhou C, Cheng Y, Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013 24 993 999
35. Eichler AF, Kahle KT, Wang DL, EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010 12 1193 1199
36. Lee HL, Chung TS, Ting LL, EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 2012 7 181
37. Park SJ, Kim HT, Lee DH, Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012 77 556 560
38. Togashi Y, Masago K, Fukudo M, Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010 5 950 955
39. Broniscer A, Panetta JC, O'Shaughnessy M, Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007 13 1511 1515
40. Meany HJ, Fox E, McCully C, Tucker C, Balis FM, The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol 2008 62 387 392
41. Marchetti S, de Vries NA, Buckle T, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/-(triple-knockout) and wild-type mice. Mol Cancer Ther 2008 7 2280 2287
42. Shi Z, Peng XX, Kim IW, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007 67 11012 11020
43. Togashi Y, Masago K, Masuda S, Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012 70 399 405
44. Deng Y, Feng W, Wu J, The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol 2014 2 116 120
45. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF, Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010 334 147 155
46. Leggas M, Panetta JC, Zhuang Y, Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006 66 4802 4807
47. Zhao J, Chen M, Zhong W, Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer 2013 14 188 193
48. Wind S, Giessmann T, Jungnik A, Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014 34 173 182
49. Zhou WJ, Zhang X, Cheng C, Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol 2012 166 1669 1683
50. Zykadia (Ceritinib) US Prescribing Information 2014 East Hanover Novartis Pharmaceuticals Corporation
51. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H, Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014 74 1023 1028
52. Gadgeel SM, Gandhi L, Riely GJ, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase study. Lancet Oncol 2014 15 1119 1128
53. Jackman DM, Holmes AJ, Lindeman N, Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006 24 4517 4520
54. Katayama T, Shimizu J, Suda K, Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009 4 1415 1419
55. Togashi Y, Masago K, Fukudo M, Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011 68 1089 1092
56. Jackman DM, Mach SL, Heng JC, Pulsed dosing of erlotinib for central nervous system progression in EGFR-mutant non-small cell lung cancer. J Clin Oncol 2013 31 Suppl abstr 8116
57. Yap TA, Vidal L, Adam J, Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010 28 3965 3972
58. Bordi P, Tiseo M, Bortesi B, Naldi N, Buti S, Ardizzoni A, Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report. Tumori 2014 100 e20 e23
59. Lin CH, Lin MT, Kuo YW, Ho CC, Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis. Lung Cancer 2014 85 479 480
60. Janjigian YY, Smit EF, Groen HJ, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014 4 1036 1045
61. Jänne PA, Ou SH, Kim DW, Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014 15 1433 1441
62. Jänne PA, Ramalingam SS, Chih-Hsin Yang J, Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014 32 15 Suppl abstr 8009
63. Sequist LV, Soria J-C, Gadgeel SM, First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014 32 15 Suppl abstr 8010
64. Kim D, Yang J, Cross D, Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM). Ann Oncol 2014 25 Suppl 4 abstr 456P
65. Kim D-W, Lee DH, Kang JH, Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). J Clin Oncol 2014 32 15 Suppl abstr 8011
66. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L, Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999 5 2884 2890
67. Chinnaiyan P, Huang S, Vallabhaneni G, Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005 65 3328 3335
68. Gow CH, Chien CR, Chang YL, Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008 14 162 168
69. Welsh JW, Komaki R, Amini A, Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013 31 895 902
70. Sperduto PW, Wang M, Robins HI, A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013 85 1312 1318
71. Pesce GA, Klingbiel D, Ribi K, Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2012 48 377 384
72. Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 27 4247 4253
73. Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M, Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review). Biomed Rep 2013 1 691 696
74. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013 8 1570 1573
75. Shaw AT, Kim DW, Mehra R, Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014 370 1189 1197
76. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ, Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012 17 1351 1375
77. Christensen JG, Zou HY, Arango ME, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007 6 12 Pt 1 3314 3322
78. Camidge DR, Bang Y, Kwak EL, Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011 29 Suppl abstr 2501
79. Mok T, Kim D-W, Wu Y-L, First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (patients) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014 32 15 Suppl abstr 8002
80. Costa DB, Shaw AT, Ou SH, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015 33 1881 1888
81. Shaw AT, Mehra R, Tan DSW, Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study. Presented at the European Society for Medical Oncology Annual Meeting. September 26-30, 2014, Madrid, Spain, abstr 1293P.
82. Gettinger SN, Bazhenova L, Salgia R, Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2014 32 15 Suppl abstr 8047
83. Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD, Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 2012 13 1376 1383
84. Ou S-H, Gadgeel S, Chiappori AA, Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (AF-002JG/NP28761, NCT01588028). J Thorac Oncol 2013 8 Suppl 2 abstr O16.07
85. Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR, Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol 2013 8 e112 e113
86. Gandhi L, Drappatz J, Ramaiya NH, Otterson GA, High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 2013 8 e3 e5
87. Friboulet L, Li N, Katayama R, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014 4 662 673
88. Felip E, Kim D-W, Mehra R, Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Presented at the European Society for Medical Oncology Annual Meeting. September 26-30, 2014; Madrid, Spain, abstr 1295P.
89. Arrondeau J, Ammari S, Besse B, Soria JC, LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Thorac Oncol 2014 9 e62 e63
90. Sakamoto H, Tsukaguchi T, Hiroshima S, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011 19 679 690
91. Ou SH, Sommers KR, Azada MC, Garon EB, Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015 20 224 226
92. Gainor JF, Sherman CA, Willoughby K, Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015 10 232 236
93. Zhang S, Wang F, Keats J, AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Res 2010 70 8 Suppl abstr LB-298
94. Rivera VM, Wang F, Anjum R, AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Res 2012 72 8 Suppl 1 abstr 1794
95. Katayama R, Khan TM, Benes C, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011 108 7535 7540
96. Maitland ML, Ou S-H I, Tolcher AW, Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a "fast follower" phase 1 trial design. J Clin Oncol 2014 32 15 Suppl abstr 2624
97. Weiss GJ, Sachdev JC, Infante JR, Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations. J Clin Oncol 2014 32 15 Suppl abstr e19005
98. Horn L, Infante JR, Blumenschein GR, A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014 32 15 Suppl abstr 8030
99. De Braud FG, Pilla L, Niger M, Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2014 32 15 Suppl abstr 2502
100. Cheng M, Quail MR, Gingrich DE, CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 2012 11 670 679
101. Awad MM, Shaw AT, ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 12 429 439
102. Johnson TW, Richardson PF, Bailey S, Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 2014 57 4720 4744
103. Gan GN, Weickhardt AJ, Scheier B, Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 2014 88 892 898